This afternoon we watched Genmab A/S drop -3.8% to a price of $20.73 per share. The Large-Cap Pharmaceutical company is now trading -43.28% below its average target price of $36.56. Analysts have set target prices ranging from $23.5 to $50.0 per share for Genmab A/S, and have given the stock an average rating of buy.
The stock has a very low short interest at 0.3%, and a short ratio of 1.39. At 0.01%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation. Finally, we also note that a very small number of institutional investors are invested in the stock, with 8.4% of Genmab A/S's shares being owned by this investor type.
Institutions Invested in Genmab A/S
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Alliancebernstein L.P. | 2% | 15,136,152 | $313,848,120 |
| 2024-09-30 | Blackrock Inc. | 1% | 4,616,963 | $95,732,730 |
| 2024-09-30 | Capital International Investors | 1% | 4,421,617 | $91,682,231 |
| 2024-09-30 | Harding Loevner LLC | 0% | 3,066,942 | $63,593,044 |
| 2024-09-30 | Wellington Management Group, LLP | 0% | 2,306,250 | $47,820,095 |
| 2024-09-30 | Renaissance Technologies, LLC | 0% | 1,786,428 | $37,041,585 |
| 2024-09-30 | Orbis Allan Gray Ltd | 0% | 1,676,793 | $34,768,303 |
| 2024-09-30 | Morgan Stanley | 0% | 1,640,390 | $34,013,487 |
| 2024-09-30 | First Trust Advisors LP | 0% | 1,393,047 | $28,884,830 |
| 2024-09-30 | Citadel Advisors Llc | 0% | 1,299,856 | $26,952,514 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Genmab A/S.
